• The U.K. Government will buy 60 million doses of the A (H1N1) adjuvanted influenza vaccine from GlaxoSmithKline PLC and 30 million from Baxter
• The French Government will buy 50 million doses of the A (H1N1) influenza vaccine from GlaxoSmithKline PLC
• The Government of Belgium will buy 12.6 million doses of the A (H1N1) influenza vaccine from GlaxoSmithKline PLC
• The Government of Finland will buy 5.3 million doses of H1N1 antigen from GlaxoSmithKline PLC
• Glaxo will provide 128 million doses of the A (H1N1) adjuvanted influenza vaccine to European countries. The European orders could contribute about $1 billlion to Glaxo sales in 2009.
• The WHO estimates that the pharmaceutical industry can produce from 1 billion to 2 billion doses of H1N1 pandemic vaccine a year.
• The Australian Government ordered 10-million doses of influenza vaccine from Commonwealth Serum Laboratories (CSL).
• HHS Sets Aside $1 Billion Toward Development of Vaccine for the Novel Influenza A (H1N1).
• The U.S. Government will have 60 million vaccine doses by the end of October, 100 million more doses by the end of November and 80 million more doses each month thereafter through March 2010.

Success with adjuvanted vaccines could have implications for the use of resources devoted to development of the next generation of vaccines and for the mechanisms the government uses to accomplish its objectives. Specifically, if adjuvanted vaccines reduced the near-term risk posed by pandemic influenza because they stretched available and planned production capacity, more resources might be made available to support the development of next generation vaccines.

European countries and US took different approaches. European countries are entering into advance supply agreements with manufacturers to provide vaccines in the event of a pandemic; those governments agree to make advance payments to guarantee the supply of vaccine in the event of an influenza pandemic. The current U.S. approach is directly subsidizing vaccine development and additional production capacity.